Generated by AI
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti-inflammatory therapies that target the complement system, particularly the C5a and C5aR pathways. The company’s portfolio centers on proprietary antibody and small-molecule programs designed to address autoimmune and other inflammatory diseases through precise modulation of immune signaling. Its current pipeline includes vilobelimab, an intravenously administered anti-C5a antibody, and an oral C5aR inhibitor in development for inflammatory indications. InflaRx serves the biotechnology and healthcare sectors, with research and operational activities in Germany and the United States. The company’s work is centered on advancing novel treatments for severe inflammatory conditions where targeted complement inhibition may play an important therapeutic role.
WebsiteWinzerlaer Str. 2
Jena, 07745
Germany
The latest articles about IFRX.
Summary of Nov 18's posts. Generated by AI.
Summary of May 8's posts. Generated by AI.
Summary of Nov 10's posts. Generated by AI.
Summary of May 6's posts. Generated by AI.
Investors talking about IFRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.